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were extrapolated to The Netherlands by direct standardisation.
RESULTS: From 2000 to 2004, the annual prevalence of DM in
The Netherlands increased from 454,000 to 641,000 patients.
Severe cardiovascular complications attributed to diabetes
increased from 18,000 to 39,000 patients. Total cost associated
with antidiabetic drug treatment and hospitalizations, attributed
to DM, increased from €442,308,000 to €822,333,000. Most of
these costs (€535,672,000 in 2004) were due to hospitalizations.
Cost of hospitalizations and cardiovascular drugs among control
subjects increased from €275,123,000 to €608,392,000. CON-
CLUSIONS: Drug treatment, hospitalisations and cost attributed
to diabetes mellitus have almost doubled between 2000 and
2004, but so did the “background” costs in the general popula-
tion, perhaps due to preventive efforts.
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OBJECTIVES: To compare cost-utility of detemir and NPH
insulin in intensive insulin therapy (IIT) of type 1 diabetes
patients, cost-utility of detemir and NPH insulin in basal-bolus
IIT or added to oral antidiabetes treatment in type 2 diabetes.
To estimate the impact of insulin detemir reimbursement on
the budget (BIA) of the National Health Fund in Poland.
METHODS: Cost-utility analysis from payers’ (Polish National
Health Fund and patient) perspective in lifetime horizon was
conducted using CORE Diabetes Model. The effectiveness data
were derived from clinical studies. The model default values and
experts’ opinion served as data sources for resource use. BIA:
Two scenarios were compared: before and after reimbursement
of insulin detemir with reimbursement limit equal to the drug
price. Population of patients treated with insulin detemir was
assumed to consist of type 1 and type 2 patients with docu-
mented episodes of severe hypoglycaemia, undergoing IIT (with
use of standard basal insulin NPH). RESULTS: CUA: Insulin
detemir in type 1 and type 2 diabetes patients is more costly and
more effective than NPH insulin in terms of patients’ life expect-
ancy and quality adjusted life years (QALYs) gained—cost
per QALY gained is: PLN161,138 (€47,512) in type 1 diabetes
treatment; PLN603,107 (€177,829), assuming use of basal-
bolus intensive insulin therapy in type 2 diabetes; PLN72,583
(€21,401), assuming use of long-acting insulin with oral antidia-
betes drugs in type 2 diabetes. A Predicted number of patients
annually treated with insulin detemir amounts to 6 736. In case
of insulin detemir reimbursement yearly public payer’s (NHF)
expenditures for long-acting insulins used in intensive insulin
therapy would increase by PLN 6,1mln (€1,8mln), i.e. 20%
compared to a current situation. CONCLUSIONS: Type 1 and
type 2 diabetes treatment with insulin detemir offers an improve-
ment of patients’ quality of life, being more costly than standard
intensive insulin therapy with NPH.
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OBJECTIVES: To estimate the cost-utility of sitagliptin (Janu-
via®) in the treatment of type 2 diabetes and impact of Januvia®
reimbursement on Polish National Health Fund (NFZ) budget.
METHODS: Cost-utility Markov model from both payers’ per-
spective (NFZ and patient) was constructed with one year time
horizon. Target population were patients with insufﬁcient glyce-
mic control with metformin monotherapy. One comparison:
sitagliptin/metformin vs metformin/glipizide was performed in
CUA. The measure of the effects was QALY. BIA was performed
from public payers’ and both payers’ (NFZ and patient) perspec-
tive in 3-year time horizon. Two reimbursement levels were con-
sidered 30% and 100%. RESULTS: Average costs of the
treatment of diabetes were 3 218.37 PLN for SIT/MET and
1 317.76 PLN for GLI/MET. Treatment effects were 0.715 QALY
for SIT/MET and 0.687 QALY for GLI/MET. ICER value for
SIT/MET vs GLI/MET was 67 027 PLN/QALY. Assuming
100%-reimbursement, annual expenses from National Health
Fund budget would raise by 9.1 (year 2008), 15.9 (2009) and 20.5
mln PLN in year 2010. In case of 30%-reimbursement of sitaglip-
tin, incremental expenditures for NFZ would be: 6.25, 10.94 and
14.07 mln PLN in years 2008, 2009 and 2010 respectively.
Assuming both payers’ perspective annual expenses from NFZ
budget and patient would raise by: 8.3 (year 2008), 14.5 (2009)
and 18.6 mln PLN in year 2010. CONCLUSIONS: Results of the
analysis indicate that sitagliptin/metformin treatment is more
effective and more expensive than strategy with metformin/
glipizide. ICER is below the acceptable threshold (83,239 PLN),
therefore treatment with SIT can be considered as cost-effective.
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OBJECTIVES: Compare costs among patients with type 2 diabe-
tes (T2D) treated with exenatide or insulin glargine. These are
injectable agents typically used after failure on oral antidiabetic
agent(s) METHODS: Data from September 2004 to September
2007 were obtained from a large retrospective claims database.
Intent-to-treat cohorts of insulin-naïve adults diagnosedwith T2D
who initiated therapy on either exenatide (N = 4090) or insulin
glargine (N = 1660). Individuals were not allowed to use the other
medication or other insulin in the one-year follow-up period.
Annual total medical costs and total diabetes relatedmedical costs
were estimated using stepwise multivariate regressions. Major
cost components were also examined using either stepwise multi-
variate regressions or a two-part model that controlled for the
probability of using the service. Smearing estimates were used to
transform estimated log costs into costs. The analyses controlled
for the potential impact of patient demographics, general health,
prior resource use, comorbidities, and timing of treatment initia-
tion. RESULTS: Initiation with exenatide compared to insulin
glargine, was associated with signiﬁcantly lower total direct
medical costs ($19,293 vs $23,782, p < 0.001) and total diabetes-
related medical costs ($7,833 vs $8,536, p < 0.0001). Initiation of
therapy with exenatide compared to insulin glargine was also
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associated with signiﬁcantly lower inpatient ($4,212 vs $7,532,
p < 0.0001), outpatient ($9,501 vs $12,885, p < 0.0001), and
emergency room costs ($82 vs $131, p < 0.0001) and signiﬁcantly
higher drug costs ($6,885 vs $5,936, p < 0.0001). Similarly, the
use of exenatide compared to insulin glargine was also associated
with signiﬁcantly lower diabetes-related inpatient ($2172 vs
$3538, p < 0.0001) and outpatient costs ($2739 vs $3249,
p < 0.0001) and signiﬁcantly higher diabetes-related drug costs
($3160 vs $2424, p < 0.0001). CONCLUSIONS: Use of
exenatide, compared to insulin glargine, was found to be associ-
ated with signiﬁcantly lower annual total direct medical costs and
total diabetes related medical costs even though diabetes related
and total drug costs were higher.
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OBJECTIVES: Compare costs among patients with type 2 dia-
betes (T2D) treated with either exenatide or sitagliptin, novel
incretin therapies with differing clinical effectiveness.
METHODS: Data from September 2004 to September 2007
were obtained from a large, retrospective, claims database. Data
from intent-to-treat cohorts of adults with T2D who initiated
therapy on either exenatide (N = 1614) or sitagliptin (N = 2482)
and who did not use the other medication in the six-month
follow-up period were examined. Total medical costs and total
diabetes-related medical costs were estimated using stepwise
multivariate regressions. Major cost components were also
examined using either stepwise multivariate regressions or a two-
part model that controlled for the probability of using the
service. Smearing estimates were used to transform estimated log
costs into costs. The analyses controls for the potential impact of
patient demographics, general health, prior resource use, comor-
bidities, and timing of treatment initiation. RESULTS: Initiation
on therapy with exenatide, compared to sitagliptin, was associ-
ated with signiﬁcantly lower total direct medical costs ($8736
vs $9995, p < 0.0001) and total diabetes-related medical
costs ($3841 vs $4002, p < 0.0001). Initiation of therapy with
exenatide compared to sitagliptin was also associated with sig-
niﬁcantly lower inpatient ($745 vs $3624, p < 0.0001), outpa-
tient ($4269 vs $5942, p < 0.0001), drug ($3467 vs $3611,
p < 0.0001) and emergency room costs ($16 vs $44, p < 0.0001).
Similarly, the use of exenatide compared to sitagliptin was
associated with signiﬁcantly lower diabetes-related inpatient
($448 vs $1847, p < 0.0001) and drug costs ($1,677 vs $1743,
p < 0.0001). CONCLUSIONS: Use of exenatide compared to
sitagliptin over six months is associated with signiﬁcantly lower
total direct medical costs and total diabetes-related medical costs.
In addition, exenatide was associated with signiﬁcantly lower
total inpatient, outpatient, drug, and emergency room costs and
signiﬁcantly lower diabetes-related inpatient and drug costs.
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OBJECTIVES: Vildagliptin is an alternative option to glitazones
when treatment intensiﬁcation is required due to loss of glycae-
mic control. Our analysis compares the clinical and cost-utility
effects of these alternative treatments. METHODS: The analysis
uses the Novartis 24-week 2354 study results comparing vilda-
gliptin 50mg BID to pioglitazone 30mg qd. The Shefﬁeld Type 2
Diabetes Model, a patient-level disease management model,
simulates use of therapies, clinical events, treatment of compli-
cations and mortality. Costs, including the £1.13 vildagliptin
daily price and £1.20 for pioglitazone, and quality-of-life (QoL)
effects, including those related to complications and weight effect
of therapies, were aggregated to obtain the incremental cost
per QALY. Uncertainty around key parameters, such as weight
effects and long-term HbA1c trends, was explored using proba-
bilistic sensitivity analysis and scenarios. RESULTS: Assuming
equal long-term HbA1c trends, the point estimate suggests that
vildagliptin is cost effective compared to pioglitazone with a cost
saving of £88 and reduction in QALYs of 0.0006. The marginal
net beneﬁt of vildagliptin compared to pioglitazone is £77 (95%
C.I. -23 to 177) with a 62% likelihood that vildagliptin is cost
effective at a UK notional £20,000 cost/QALY threshold. The
main driver is the cheaper cost of vildagliptin. There is a small
QALY loss due to fewer CHD events with pioglitazone arising
from its superior lipid effects, although this is mitigated by the
QALY gain due to the weight neutrality of vildagliptin. The
long-term HbA1c trends are highly important but uncertain
assumptions, and conclusions about the cost effectiveness could
change if evidence for different trends emerged. CONCLU-
SIONS: The expected differences in lifetime costs and QALYs
between vildagliptin and pioglitazone are small, with consider-
able uncertainty around key parameters. Results suggest a 62%
likelihood that vildagliptin is cost effective compared to piogli-
tazone at a £20,000 cost/QALY threshold assuming similar long-
term HbA1c trends.
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OBJECTIVES: The aim of this analysis was to evaluate the
long-term clinical and economic outcomes associated with
insulin detemir and Neutral Protamine Hagedorn (NPH) insulin
in combination with mealtime insulin aspart in patients with type
1 diabetes in the Belgian, French, German, Italian and Spanish
settings. METHODS: A published and validated computer simu-
lation model of diabetes (CORE Diabetes Model) was used to
make long-term projections of life-expectancy, quality-adjusted
life expectancy and direct medical costs. The analysis was based
on patient characteristics and treatment effects from a 2-year,
multi-national, open-label, randomized, controlled trial. In the
trial, insulin detemir was associated with signiﬁcant improve-
ments in glycemic control after 24 months (HbA1c 7.36% versus
7.58%, mean difference -0.22%, P = 0.022) and major hypogly-
cemic events (69% risk reduction, P = 0.001) versus NPH.
Patients treated with detemir gained less weight (1.7 versus 2.7
kg, P = 0.024). Events were projected for a time horizon of 50
years. RESULTS: Basal-bolus therapy with insulin detemir was
projected to improve quality-adjusted life expectancy by 0.45
years (7.04 versus 6.59 years) versus NPH in the German setting.
Similar improvements were observed in the other countries
(Belgium +0.52, France +0.55, Italy +0.58 and Spain +0.40
years). Insulin detemir was associated with cost savings in
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